Policy / Regulatory

China’s NMPA, MPS, and NHC Announce Updates to Narcotics and Psychotropic Substances Catalog

CompanyDeals

China Resources Biopharmaceutical Partners with Hefei Institute and Afana Bio for Joint Lab

CompanyDrug

XZenith Biopharm Completes Enrollment in Phase II Study for Proton Pump Inhibitor

CompanyDrug

Adagene Inc. Presents Positive Interim Results for ADG126 at AACR Annual Meeting

CompanyDrug

BeiGene and SpringWorks Therapeutics Report Positive Phase Ib Results for Lifirafenib and Mirdametinib Combination

CompanyDrug

HanchorBio Receives FDA Approval for Multi-Region Clinical Study of HCB101 Fusion Protein

CompanyDeals

Hainan’s Boao Lecheng Partners with Sonova to Advance Hearing Health Solutions in China

CompanyDeals

Nanjing Chamlion Laser Technology Secures RMB 236 Million in Series B Financing for Dental 3D Printing

CompanyDrug

HutchMed’s Elunate Receives NMPA Review for Second-Line Gastric Cancer Treatment

CompanyDrug

HuidaGene Receives CDE IND Approval for Ophthalmology Gene Therapy HG004

CompanyDrug

CBMG’s C-CAR031 Shows Promising Results in Phase I Study for Hepatocellular Carcinoma

Company

CanSino Biologics Reports 2022 Revenue Drop and Increased Losses Amid COVID-19 Vaccine Market Shifts